David A. Liebner
Papers
1
Total Citations
21
H-Index
1
About
David A. Liebner is a physician-scientist whose research focuses on the intersection of immunotherapy resistance and tumor biology, with a particular emphasis on melanoma and sarcoma. His major contributions include identifying the adrenal gland as a sanctuary site for metastases following PD-1 blockade, a finding that illuminated a novel mechanism of intrapatient heterogeneous treatment response. This work, published in a 2018 case series (21 citations), demonstrated that despite systemic responses to pembrolizumab, certain organs—like the adrenal gland—can harbor resistant tumor clones, challenging the assumption of uniform drug penetration or immune activity. Liebner’s research has implications for understanding immune evasion and optimizing combination therapies. Beyond this, he has advanced clinical trials in sarcoma, exploring targeted and immunotherapeutic strategies for rare, difficult-to-treat cancers. His work is widely cited for bridging clinical observation with mechanistic insight, and he is recognized for his contributions to precision oncology and the study of metastatic heterogeneity.
Research Focus
Key Achievements
Top Papers
- 1